|Mr. Lonnel Coats||Pres, CEO & Director||1,15M||N/A||1965|
|Mr. Jeffrey L. Wade||Exec. VP of Corp. & Admin. Affairs and CFO||655,18k||N/A||1965|
|Mr. Brian T. Crum||VP, Gen. Counsel & Sec.||536,92k||N/A||1973|
|Dr. Alan J. Main||Exec. VP of Innovation & Chemical Sciences||560,17k||N/A||1954|
|Dr. Robert J. Lefkowitz||Consultant & Independent Director||50k||N/A||1944|
|Mr. James F. Tessmer||VP of Fin. & Accounting||N/A||N/A||1960|
|Chas Schultz||Exec. Director of Corp. Communications & Patient Advocacy||N/A||N/A||N/A|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Juni 2021, lautet 10. Die grundlegenden Scores sind Audit: 7, Vorstand: 9, Shareholderrechte: 7, Kompensation: 10.